{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:07:23Z","timestamp":1754161643733,"version":"3.41.2"},"reference-count":54,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Food Allergy"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:p>Omalizumab is approved for the management of immunoglobulin E\u2010mediated food allergy in individuals ages \u2265 1 year. Approval for food allergy followed the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) study, which\n demonstrated that omalizumab increases the threshold dose of multiple food allergens needed to elicit an allergic reaction. Despite the demonstrated efficacy in food allergy and favorable safety profile, many questions remain. This review addresses the efficacy of omalizumab for the management\n of food allergy, as monotherapy, and in conjunction with oral immunotherapy. Safety in children is paramount, and this review addresses noted adverse events of anaphylaxis and malignancy. There is minimal knowledge with regard to the real-world impact on food allergy\u2010related quality\n of life. Many questions still remain, including identifying who is the ideal patient for omalizumab, determining the role of oral food challenges before and during therapy with omalizumab, evaluating food allergy tolerance while on treatment, and optimizing the cost-effectiveness of this efficacious\n and well-tolerated management option for food allergy.<\/jats:p>","DOI":"10.2500\/jfa.2025.7.250004","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T04:32:01Z","timestamp":1753763521000},"page":"7-13","source":"Crossref","is-referenced-by-count":1,"title":["Omalizumab in food allergy: Risks and benefits"],"prefix":"10.2500","volume":"7","author":[{"given":"S. Shahzad","family":"Mustafa","sequence":"first","affiliation":[{"name":"From the Rochester Regional Health, Rochester, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Sokol","sequence":"additional","affiliation":[{"name":"Schreiber Allergy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"e9\u2013e17","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.anai.2022.12.031","article-title":"The epidemiology of multifood allergy in the United States: a population-based study","volume":"130","author":"Warren","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"e0262851","DOI":"10.1371\/journal.pone.0262851","article-title":"Allergy to Peanuts imPacting Emotions And Life (APPEAL): the impact of peanut allergy on children, teenagers, adults and caregivers in the UK and Ireland","volume":"17","author":"Tsoumani","year":"2022","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40521-022-00306-5","article-title":"The economic burden of food allergy: what we know and what we need to learn","volume":"9","author":"Fong","year":"2022","journal-title":"Curr Treat Options Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1016\/j.jaip.2024.08.006","article-title":"Prevalence and characteristics of accidental ingestions among pediatric food allergy patients","volume":"12","author":"Hsu","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13696998.2024.2386819","article-title":"Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis","volume":"27","author":"Sindher","year":"2024","journal-title":"J Med Econ"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.anai.2023.01.027","article-title":"Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp","volume":"130","author":"Portnoy","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jaip.2021.12.022","article-title":"Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia","volume":"10","author":"Patrawala","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"B12","doi-asserted-by":"crossref","first-page":"e187430642206130","DOI":"10.2174\/18743064-v16-e2206130","article-title":"Real-life effectiveness of omalizumab in patients with severe allergic asthma: RELIEF study","volume":"16","author":"Al Ahmad","year":"2022","journal-title":"Open Respir Med J"},{"key":"B13","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2024.03.019","article-title":"A practical guide for implementing omalizumab therapy for food allergy","volume":"153","author":"Casale","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.5415\/apallergy.2021.11.e27","article-title":"Successful treatment of a patient with adult food allergy and severe asthma using omalizumab","volume":"11","author":"Nishie","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5414\/ALX02372E","article-title":"Treatment of severe cow's milk allergy with omalizumab in an adult","volume":"7","author":"Klein","year":"2023","journal-title":"Allergol Select"},{"key":"B18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaip.2018.09.015","article-title":"Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab","volume":"7","author":"Yee","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12016-021-08902-0","article-title":"Combining anti-IgE monoclonal antibodies and oral immunotherapy for the treatment of food allergy","volume":"62","author":"Guilleminault","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"e075253","DOI":"10.1136\/bmjopen-2023-075253","article-title":"Efficacy of biological agents combined with oral immunotherapy (OIT) for food allergy: a protocol for a systematic review and meta-analysis","volume":"14","author":"Honda","year":"2024","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/pai.12767","article-title":"Combining anti-IgE with oral immunotherapy","volume":"28","author":"Lin","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstr\u00f6m","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2023.03.030","article-title":"Anti-immunoglobulin E for food allergy","volume":"131","author":"Dantzer","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.anai.2023.04.023","article-title":"Treatment of food allergy: oral immunotherapy, biologics, and beyond","volume":"131","author":"Sindher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jaip.2022.04.015","article-title":"Perceptions on home-administration of biologics in the context of severe asthma: an international qualitative study","volume":"10","author":"Flokstra-de Blok","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaip.2022.12.046","article-title":"Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1208\/s12248-015-9821-x","article-title":"Evaluation of IgE antibodies to omalizumab (Xolair\u00ae) and their potential correlation to anaphylaxis","volume":"18","author":"Baker","year":"2016","journal-title":"AAPS J"},{"key":"B36","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","article-title":"Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study","volume":"138","author":"Lieberman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir Med"},{"key":"B39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12325-022-02308-w","article-title":"Identifying patients for self-administration of omalizumab","volume":"40","author":"Murphy","year":"2023","journal-title":"Adv Ther"},{"key":"B41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"crossref","first-page":"e13743","DOI":"10.1111\/pai.13743","article-title":"The burden of food allergy on children and teens: a systematic review","volume":"33","author":"Golding","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anai.2024.09.020","article-title":"Community and academic allergists' perspectives on integrating biologics into food allergy care: a qualitative study","volume":"134","author":"Fisher","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaci.2024.09.031","article-title":"The use and implementation of omalizumab as food allergy treatment: consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology.","volume":"155","author":"Anagnostou","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2024.07.034","article-title":"Food allergy yardstick: where does omalizumab fit?","volume":"134","author":"Anagnostou","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2222.2008.03120.x","article-title":"Development and validation of a self-administered Food Allergy Quality of Life Questionnaire for children","volume":"39","author":"Flokstra-de Blok","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaip.2015.07.023","article-title":"Differences in caregiver food allergy quality of life between tertiary care, specialty clinic, and caregiver-reported food allergic populations","volume":"4","author":"Ward","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1398-9995.2009.01968.x","article-title":"Development and validation of the Food Allergy Quality of Life Questionnaire - Adult Form","volume":"64","author":"Flokstra-de Blok","year":"2009","journal-title":"Allergy"},{"key":"B50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B51","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jaip.2024.06.023","article-title":"The cost-effectiveness of omalizumab for treatment of food allergy","volume":"12","author":"Shaker","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2500\/jfa.2023.5.230009","article-title":"Asthma and food allergy: a nuanced relationship","volume":"5","author":"Stukus","year":"2023","journal-title":"J Food Allergy"},{"key":"B53","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jama.2011.999","article-title":"Physician stewardship of health care in an era of finite resources","volume":"306","author":"Reuben","year":"2011","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.anai.2024.07.012","article-title":"Role of an embedded health system specialty pharmacy on prescription of biologics in allergy\/immunology","volume":"133","author":"Patrawala","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Journal of Food Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/jfa\/2025\/00000007\/00000001\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T04:32:30Z","timestamp":1753763550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/jfa.2025.7.250004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,6,1]]}},"alternative-id":["2689-0267(20250601)7:1L.7;1-"],"URL":"https:\/\/doi.org\/10.2500\/jfa.2025.7.250004","relation":{},"ISSN":["2689-0267"],"issn-type":[{"type":"print","value":"2689-0267"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}